Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 mai 2023 18h06 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 avr. 2023 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., April 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announces CFO Resignation
05 avr. 2023 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 mars 2023 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
09 mars 2023 07h00 HE
|
Fulcrum Therapeutics, Inc.
― Company is working to address clinical hold on the Investigational New Drug application for FTX-6058 for the potential treatment of sickle cell disease ― ― FTX-6058 data from 12 mg cohort of Phase...
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
06 mars 2023 16h05 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
24 févr. 2023 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 févr. 2023 17h27 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
08 févr. 2023 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
17 janv. 2023 23h15 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...